Vistagen Therapeutics (NASDAQ: VTGN), based in South San Francisco, presented exploratory findings from two clinical trials evaluating its intranasal nasal spray candidate, fasedienol, at the upcoming Psych Congress 2026 in New Orleans. The data, drawn from post-hoc analyses of the PALISADE-4 Phase 3 trial and a prespecified subpopulation analysis in the Phase 2a repeat-dose study, focused on participants with very severe social anxiety disorder—defined by a baseline Liebowitz Social Anxiety Scale score of 95 or higher.
Vistagen’s Fasedienol Shows Promise in Severe Social Anxiety Trials
Exploratory data from two Phase 3 and Phase 2a trials highlights statistically significant SUDS score improvements in participants with very severe social anxiety disorder.
SL
Sophie Laurent · FX & Rates Desk · 26 Sept 2026 · 07:37 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
SL
Written by
Sophie Laurent
FX & Rates Desk
Sophie covers currency markets and central bank policy across Europe, with a focus on how rate decisions ripple through FX pairs. She has been tracking the ECB's policy path since the start of the current easing cycle.
More from Sophie Laurent →
